Fibroblast growth factor 23: roles in health and disease - PubMed (original) (raw)

Review

. 2005 Sep;16(9):2565-75.

doi: 10.1681/ASN.2005050573. Epub 2005 Jul 20.

Affiliations

• PMID: 16033853
• DOI: 10.1681/ASN.2005050573

Review

Fibroblast growth factor 23: roles in health and disease

Erik A Imel et al. J Am Soc Nephrol. 2005 Sep.

No abstract available

PubMed Disclaimer

Similar articles

• [Regulatory effect of FGF23 on phosphate and vitamin D metabolism].
  Yamashita T. Yamashita T. Nihon Rinsho. 2005 Oct;63 Suppl 10:519-22. Nihon Rinsho. 2005. PMID: 16279693 Review. Japanese. No abstract available.
• Fibroblast growth factor 23 and its receptors.
  Yu X, White KE. Yu X, et al. Ther Apher Dial. 2005 Aug;9(4):308-12. doi: 10.1111/j.1744-9987.2005.00287.x. Ther Apher Dial. 2005. PMID: 16076372 Review.
• [Autosomal dominant hypophosphatemic rickets/osteomalacia].
  Tanaka H. Tanaka H. Nihon Rinsho. 2005 Oct;63 Suppl 10:529-33. Nihon Rinsho. 2005. PMID: 16279695 Review. Japanese. No abstract available.
• The role of fibroblast growth factor 23 in renal disease.
  Jonsson KB. Jonsson KB. Nephrol Dial Transplant. 2005 Mar;20(3):479-82. doi: 10.1093/ndt/gfh701. Nephrol Dial Transplant. 2005. PMID: 15735238 Review. No abstract available.
• [Genetics of hypophosphosphatemia].
  Salles JP. Salles JP. Arch Pediatr. 2006 Jun;13(6):522-4. doi: 10.1016/j.arcped.2006.03.111. Epub 2006 May 12. Arch Pediatr. 2006. PMID: 16697626 French. No abstract available.

Cited by

• Burosumab Efficacy and Safety in Patients with X-Linked Hypophosphatemia: Systematic Review and Meta-analysis of Real-World Data.
  Kiafzezi D, Stamati A, Karagiannis T, Goulis DG, Christoforidis A. Kiafzezi D, et al. Calcif Tissue Int. 2024 Sep;115(3):229-241. doi: 10.1007/s00223-024-01250-z. Epub 2024 Jul 15. Calcif Tissue Int. 2024. PMID: 39008126
• Diagnosis, treatment, and management of rickets: a position statement from the Bone and Mineral Metabolism Group of the Italian Society of Pediatric Endocrinology and Diabetology.
  Baroncelli GI, Comberiati P, Aversa T, Baronio F, Cassio A, Chiarito M, Cosci O di Coscio M, De Sanctis L, Di Iorgi N, Faienza MF, Fintini D, Franceschi R, Kalapurackal M, Longhi S, Mariani M, Pitea M, Secco A, Tessaris D, Vierucci F, Wasniewska M, Weber G, Mora S. Baroncelli GI, et al. Front Endocrinol (Lausanne). 2024 Apr 19;15:1383681. doi: 10.3389/fendo.2024.1383681. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38706696 Free PMC article. Review.
• Intact FGF23 concentration in healthy infants, children, and adolescents, and diagnostic usefulness in patients with X-linked hypophosphatemic rickets.
  Baroncelli GI, Sessa MR, Pelosini C, Bertelloni S, Michelucci A, Toschi B, Piaggi P, Peroni D, Comberiati P. Baroncelli GI, et al. J Endocrinol Invest. 2024 Apr;47(4):873-882. doi: 10.1007/s40618-023-02202-4. Epub 2023 Nov 22. J Endocrinol Invest. 2024. PMID: 37991698 Free PMC article.
• X-Linked Hypophosphatemic Rickets: Multisystemic Disorder in Children Requiring Multidisciplinary Management.
  Baroncelli GI, Mora S. Baroncelli GI, et al. Front Endocrinol (Lausanne). 2021 Aug 6;12:688309. doi: 10.3389/fendo.2021.688309. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34421819 Free PMC article. Review.
• Population Pharmacokinetics and Pharmacodynamics of Burosumab in Adult and Pediatric Patients With X-linked Hypophosphatemia.
  Lee SK, Gosselin NH, Taylor J, Roberts MS, McKeever K, Shi J. Lee SK, et al. J Clin Pharmacol. 2022 Jan;62(1):87-98. doi: 10.1002/jcph.1950. Epub 2021 Aug 27. J Clin Pharmacol. 2022. PMID: 34352114 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Wolters Kluwer

• Other Literature Sources

  • The Lens - Patent Citations

• Medical

  • MedlinePlus Health Information